Product Images Edarbyclor

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Edarbyclor NDC 75929-230 by Pharma Packaging Solutions, Llc Dba Tjoapack Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle1 - Bottle1

Bottle1 - Bottle1

Figure 1.a - edarbyclor 01

Figure 1.a - edarbyclor 01

Figure 1.b - edarbyclor 02

Figure 1.b - edarbyclor 02

Not available*

Figure 1.c - edarbyclor 03

Figure 1.c - edarbyclor 03

This is a blood pressure chart that shows the diastolic blood pressure readings in millimeters of mercury (mmHg) at different points. The text indicates that the diastolic blood pressure should be less than 90 mmHg (9%) for optimal health. The chart also includes the names and doses of certain medications such as Edarbyclor (40/25mg), Azilsartan medoxomil (80mg), and Chlorthalidone (25mg). The "Baseline Diastolic BP" refers to the initial diastolic blood pressure measurement.*

Figure 1.d - edarbyclor 04

Figure 1.d - edarbyclor 04

Chemical Structure - edarbyclor 05

Chemical Structure - edarbyclor 05

Chemical Structure - edarbyclor 06

Chemical Structure - edarbyclor 06

Figure 2 - edarbyclor 07

Figure 2 - edarbyclor 07

Population Description: This description provides information about the population involved in a study or evaluation. It includes details such as age range (greater than 65 years or 18-45 years), gender (females or males), race (whites or blacks), renal impairment severity (mild, moderate, severe, or end-stage renal disease), hepatic impairment severity (mild, moderate, severe, or normal), and the presence of pediatric patients. Based on the text, there are also recommendations for dose adjustment, with the notation "No dose adjustment" being mentioned multiple times. Furthermore, there is an indication of "No experience" in certain cases. Overall, this text provides a description of the studied population's characteristics and recommendations related to dose adjustments.*

Figure 3 - edarbyclor 08

Figure 3 - edarbyclor 08

PRINCIPAL DISPLAY PANEL - 40 mg/12.5 mg Tablet Bottle Label - edarbyclor 09

PRINCIPAL DISPLAY PANEL - 40 mg/12.5 mg Tablet Bottle Label - edarbyclor 09

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.